
Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

The National Cancer Institute (NCI) estimates that sexual dysfunction rates among cancer survivors range anywhere between 40% and 100%

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

A look at what's new in the 2011 National Patient Safety Goals

Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.

At NCONN 2010, Matthew Zachary, musician, brain cancer survivor, and founder of the I'm Too Young For This! Cancer Foundation (i[2]y) discussed empowering young adults with cancer.

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

A recent study in the journal The Lancet suggests long-term, low-dose aspirin use reduces the risk of cancer-related death.

For most cancers, African Americans continue to have the highest death rates and shortest survival rates among racial and ethnic populations in the United States.

A black Labrador retriever was able to detect colorectal cancer >90% of the time when sniffing a patient%u2019s breath or stool sample.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.